AbbVie Enters into a Collaboration to Develop Monoclonal Antibody Therapy for Preventing COVID-19

Shots:

• AbbVie collaborated with Harbour BioMed (HBM), Utrecht University (UU) and Erasmus Medical Center (EMC) to develop a novel Ab to prevent and treat COVID-19. The collaboration focuses on advancing 47D11, discovered by UU, EMC and HBM that targets the domain of the spike protein of SARS-CoV-2
• AbbVie will support UU, EMC, and HBM in preclinical activities, while simultaneously preparing late-stage pre/ clinical development. AbbVie to get an option to exclusively license the Ab from the three parties for WW clinical development and commercialization
• The Ab discovered by UU, EMC, and HBM is based on the mechanism by which it targets the virus and on its developability as a fully human protein. The is designed to facilitate its development and minimize immune-related side effects

Click here to read full press release/ article | Ref: AbbVie | Image: AbbVie